Merck, Novo Holdings and several smaller drug developers are partnering with the Biotechnology Innovation Organization (BIO) trade group in a new initiative to spur research and development in the fight against superbugs. The “Working to Fight AMR” awareness and lobbying campaign tackles the problem of drug development in antimicrobial-resistant drugs.
Cipla's key priority for the upcoming quarters is to drive further growth in chronic portfolio and to improve execution on the acute portfolio by focusing on micromarket segments in India, the company said in an investor presentation.
Achaogen has just about wrapped up its going-out-of-business sale, with a small group of buyers from around the globe picking up its main antibiotic assets for a song. And they’re just one short telephone auction away from selling their last remaining clinical program.
Achaogen is making its second set of cuts in under four months. The latest restructuring is intended to slash up to 40% of Achaogen’s expenses, enabling the antibiotic company to hunker down and search for an exit.
Look for yet another player working in the immuno-oncology space to enter the clinic with a nimble team of experienced execs focused on dismantling immunosuppression.
It took a few years more than expected, but Tetraphase finally has a product to sell.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for ZEMDRI when administered in the hospital inpatient setting.
A few weeks after the FDA green-lighted Achaogen’s $AKAO antibiotic Zemdri (plazomicin) for urinary tract infections but shunted aside their application on bloodstream infections, the biotech is laying off rank-and-file researchers and letting go its top research execs.
Achaogen got some anticipated good news Tuesday with an FDA nod for its high-powered antibiotic Zemdri, but it wasn't an unqualified win. Zemdri will make its debut as a treatment for drug-resistant urinary tract infections with a black-box warning, and it missed out on a second use—bloodstream infections—it had hoped to win this first go-round.
Achaogen got a mixed outcome from the FDA advisory committee meeting on its antibiotic plazomicin yesterday, with a vote in favor of approval for complicated urinary tract infections but against its use in bloodstream infections.